Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV3 | Q8NET8 | 2/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 2/20 | 0.38 |
| ▸ | PTPN7 | P35236 | 3/20 | 0.38 |
| ▸ | DUSP3 | P51452 | 3/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | MPL | P40238 | 2/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 5/20 | 0.35 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.35 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8511924 | 1.00 | TRPV3 (0.40) | TRPV3EPHX1ARPTPN7DUSP3 | |
| SCHEMBL16464215 | 1.00 | TRPV3 (0.40) | TRPV3EPHX1ARPTPN7DUSP3 | |
| SCHEMBL15157757 | 0.83 | SLC6A4 (0.44) | EPHX1ARMPLAKT1PDE2A | |
| SCHEMBL14980642 | 0.83 | ANPEP (0.39) | EPHX1ARMPLAKT1PDE2A | |
| SCHEMBL297430 | 0.83 | SLC6A4 (0.44) | EPHX1ARMPLAKT1PDE2A | |
| SCHEMBL2397716 | 0.83 | SLC6A4 (0.44) | EPHX1ARMPLAKT1PDE2A | |
| SCHEMBL8511124 | 0.81 | IDO1 (0.45) | ADRB2ADRB1 | |
| SCHEMBL8511122 | 0.81 | IDO1 (0.45) | ADRB2ADRB1 | |
| Hydrochloric Acid SCHEMBL15758051 | 0.81 | AKT1 (0.43) | EPHX1ARPTPN7DUSP3MPL | |
| SCHEMBL12494095 | 0.80 | MPL (0.38) | EPHX1ARPTPN7DUSP3KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2643313-B9 | QUINAZOLINE CARBOXAMIDE AZETIDINES | MERCK PATENT GMBH (DE) | 2017-02-22 | — | — | EP | disclosed |
| EP-2643313-B1 | QUINAZOLINE CARBOXAMIDE AZETIDINES | MERCK PATENT GMBH (DE) | 2016-06-29 | — | — | EP | disclosed |
| US-8946247-B2 | Quinazoline carboxamide azetidines | MERCK PATENT GMBH (DE) | 2015-02-03 | — | — | US | disclosed |
| EP-2643313-A1 | QUINAZOLINE CARBOXAMIDE AZETIDINES | Merck Patent GmbH (DE) | 2013-10-02 | — | — | EP | disclosed |
| US-20130252942-A1 | QUINAZOLINE CARBOXAMIDE AZETIDINES | MERCK PATENT GMBH (DE) | 2013-09-26 | — | — | US | disclosed |
| CN-103228649-A | Quinazoline carboxamide azetidines | MERCK PATENT GMBH | 2013-07-31 | — | — | CN | disclosed |
| WO-2012069146-A1 | QUINAZOLINE CARBOXAMIDE AZETIDINES | MERCK PATENT GMBH (DE) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252942-A1 | QUINAZOLINE CARBOXAMIDE AZETIDINES | AZI2, NQO2, ABL1 | TRPV3 4298/4885EPHX1 3551/4885AR 3161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.